High-Potent Oral Solid Dosage Contract Manufacturing Market to Reach USD 15.32 Billion by 2035 at 8.8% CAGR

High-Potent Oral Solid Dosage Contract Manufacturing Market

DE, UNITED STATES, February 25, 2026 /EINPresswire.com/ --
The high-potent oral solid dosage (HP-OSD) contract manufacturing market is projected to grow from USD 6.59 billion in 2025 to USD 15.32 billion by 2035, reflecting a steady value-based CAGR of 8.8%. This expansion is largely driven by the rising demand for specialized treatments in oncology and other chronic disease areas, where high-potency APIs require advanced containment and manufacturing expertise. As more high-potency compounds advance through clinical pipelines, pharmaceutical companies increasingly rely on specialized CDMOs to ensure safety, compliance, and scalability.

Market snapshot: global market 2025 - 2035

Market size in 2025: USD 6.59 billion
Market size in 2035: USD 15.32 billion
CAGR (2025–2035): 8.8%
Leading dosage form and share: Tablets at 46.5%
Leading formulation technology and share: Fluid bed granulation at 34.2%
Key growth drivers: Rising oncology therapies and need for high-containment manufacturing
Key growth regions: Strong expansion in Asia (especially China and South Korea) and established markets in North America and Europe

Market Momentum (YoY Path)

The HP-OSD contract manufacturing market demonstrates consistent upward momentum through the forecast period. Starting at USD 6.59 billion in 2025, the market is expected to build steadily, supported by ongoing investments in containment technologies and formulation innovations. By 2028 and into 2030, growth accelerates with broader adoption of continuous manufacturing and digital tools. Momentum continues into 2031 and 2033 as oncology pipelines mature and outsourcing trends strengthen, culminating in the projected USD 15.32 billion valuation by 2035 at the sustained 8.8% CAGR.

Why the Market is Growing

The high-potent oral solid dosage contract manufacturing market is expanding due to the increasing prevalence of chronic diseases, particularly cancer, which drives demand for targeted high-potency therapies. The rise in oncology and specialty drugs necessitates advanced high-containment capabilities, prompting greater reliance on CDMOs equipped for safe handling of potent compounds. Investments in containment infrastructure, automation, and flexible manufacturing platforms further support scalability and efficiency, positioning the market for sustained growth.

Drivers, Opportunities, Trends, Challenges

Drivers

The market benefits from the growing need for high-potency treatments in oncology, hormonal disorders, autoimmune diseases, and other chronic conditions. Rising demand for targeted therapies and the expansion of high-potency API pipelines push pharmaceutical companies toward specialized CDMOs with containment technologies.

Opportunities

Adoption of continuous manufacturing, automation, and AI-driven optimization presents significant growth potential. Modular containment solutions, flexible platforms, and partnerships to accelerate drug development timelines offer avenues for expansion. Emerging markets in Asia and Latin America provide untapped opportunities for cost-effective manufacturing footprints.

Trends

Digital transformation is reshaping operations with AI predictive analytics, digital twins, and real-time monitoring to boost efficiency and quality. Sustainability efforts include green containment technologies, solvent recovery, and biodegradable packaging. Blockchain enhances supply chain traceability, while regulatory alignment with FDA, EMA, and other standards drives cleanroom and GMP investments.

Challenges

Stringent regulatory compliance demands substantial investments in facility upgrades, isolators, and negative pressure systems, increasing costs. Preventing cross-contamination in multi-product facilities requires rigorous cleaning validation, while talent shortages in high-potency handling and limited awareness in emerging markets pose operational constraints.

Competitive Landscape

The high-potent oral solid dosage contract manufacturing market features strong competition among leading CDMOs investing in containment, digital tools, and high-potency capabilities. Key players include Catalent Inc., Lonza Group, WuXi AppTec, Pfizer Inc. (including Pfizer CentreOne), and Recipharm, which offer end-to-end services from formulation to commercial production. Other notable contributors are PCI Pharma Services, CordenPharma International, Piramal Pharma Solutions, and additional firms advancing containment and regulatory compliance.

Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-17655

Scope of the Report

Quantitative units: USD billion for value
Segmentation: Dosage forms (tablets, orally disintegrating tablets, hard gelatine capsules, etc.); formulation technologies (fluid bed granulation, roller compaction, etc.); therapy areas (cancer, hormonal disorders, etc.); services (API manufacturing, drug product development, etc.); end users (big pharma/biotech, small & medium, etc.)
Regions: North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa
Countries: United States, Canada, Brazil, Mexico, Germany, France, United Kingdom, Italy, Spain, China, India, Japan, South Korea, Australia, GCC Countries, South Africa (among others covered)

FAQ

What is the projected size of the high-potent oral solid dosage contract manufacturing market in 2035? The market is expected to reach USD 15.32 billion by 2035.

What is the CAGR for the high-potent oral solid dosage contract manufacturing market from 2025 to 2035? The value-based CAGR is 8.8% over the period.

Which dosage form holds the leading share in 2025? Tablets are expected to dominate with a 46.5% market share in 2025.

Which formulation technology leads in 2025? Fluid bed granulation is projected to hold a 34.2% share in the formulation technology segment in 2025.

Explore More Related Studies Published by FMI Research:

Pharmaceutical Solid Dosage Contract Manufacturing Market:https://www.futuremarketinsights.com/reports/pharmaceutical-solid-dosage-contract-manufacturing-market

Oral Solid Dosage Pharmaceutical Formulation Market:https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market

Contract Dose Manufacturing Market:https://www.futuremarketinsights.com/reports/contract-dose-manufacturing-market

IVD Contract Manufacturing Market:https://www.futuremarketinsights.com/reports/ivd-contract-manufacturing-market

Biologics Contract Manufacturing Market:https://www.futuremarketinsights.com/reports/biologics-contract-manufacturing-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Sudip Saha
Future Market Insights Inc.
+1 347-918-3531
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.